Drug Profile

CR 003 - Crescent Biopharma

Alternative Names: CR-003 - Crescent Biopharma; PR-023-Paragon Therapeutics; SKB-105

Latest Information Update: 09 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Paragon Therapeutics; Sichuan Kelun-Biotech Biopharmaceutical
Developer Paragon Therapeutics
Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

04 Dec 2025 CR 003 licensed to Crescent Biopharma worldwide excluding greater China
04 Dec 2025 Preclinical trials in Solid tumours in USA (Parenteral)
04 Dec 2025 Crescent Biopharma plans a phase I/II trial for Solid tumours in China, Macau, Taiwan, Hong Kong (Parenteral) in first quarter of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com